Trials / Completed
CompletedNCT02354105
A Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Life
A Noninterventional Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Practice
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 680 (actual)
- Sponsor
- UCB Biopharma S.P.R.L. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose is to assess the effectiveness of certolizumab pegol in patients with axial spondyloarthritis under routine clinical practice.
Conditions
Timeline
- Start date
- 2015-01-12
- Primary completion
- 2018-03-09
- Completion
- 2018-03-09
- First posted
- 2015-02-03
- Last updated
- 2019-03-11
Locations
100 sites across 6 countries: Belgium, Germany, Greece, Italy, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02354105. Inclusion in this directory is not an endorsement.